JP7471685B2 - 新規な化合物およびそれを含むがんの予防または治療用薬学組成物 - Google Patents

新規な化合物およびそれを含むがんの予防または治療用薬学組成物 Download PDF

Info

Publication number
JP7471685B2
JP7471685B2 JP2022525398A JP2022525398A JP7471685B2 JP 7471685 B2 JP7471685 B2 JP 7471685B2 JP 2022525398 A JP2022525398 A JP 2022525398A JP 2022525398 A JP2022525398 A JP 2022525398A JP 7471685 B2 JP7471685 B2 JP 7471685B2
Authority
JP
Japan
Prior art keywords
substituted
cancer
alkyl
unsubstituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500857A (ja
Inventor
ジン ユン、ヨ
ヘ イ、イン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Holosmedic
Original Assignee
Holosmedic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holosmedic filed Critical Holosmedic
Publication of JP2023500857A publication Critical patent/JP2023500857A/ja
Application granted granted Critical
Publication of JP7471685B2 publication Critical patent/JP7471685B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
JP2022525398A 2019-10-31 2020-10-29 新規な化合物およびそれを含むがんの予防または治療用薬学組成物 Active JP7471685B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928398P 2019-10-31 2019-10-31
US62/928,398 2019-10-31
PCT/KR2020/014884 WO2021086038A1 (fr) 2019-10-31 2020-10-29 Nouveau composé et composition pharmaceutique le comprenant pour prévenir ou traiter un cancer

Publications (2)

Publication Number Publication Date
JP2023500857A JP2023500857A (ja) 2023-01-11
JP7471685B2 true JP7471685B2 (ja) 2024-04-22

Family

ID=75716034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525398A Active JP7471685B2 (ja) 2019-10-31 2020-10-29 新規な化合物およびそれを含むがんの予防または治療用薬学組成物

Country Status (11)

Country Link
US (1) US20230019094A1 (fr)
EP (1) EP4053127A4 (fr)
JP (1) JP7471685B2 (fr)
KR (1) KR102622152B1 (fr)
CN (1) CN114630830A (fr)
AU (1) AU2020374208B2 (fr)
BR (1) BR112022007998A2 (fr)
CA (1) CA3159791A1 (fr)
IL (1) IL292631A (fr)
MX (1) MX2022004739A (fr)
WO (1) WO2021086038A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220148758A (ko) * 2021-04-29 2022-11-07 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030907A1 (fr) 2001-10-09 2003-04-17 Myriad Genetics, Inc. Mimetiques de coudes inverses et composition et procedes afferents
WO2004035581A1 (fr) 2002-10-18 2004-04-29 Ono Pharmaceutical Co., Ltd. Composes de derives spiroheterocycliques et medicaments contenant lesdits composes comme principe actif
JP2011500774A (ja) 2007-10-26 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体
JP2011522037A (ja) 2008-06-06 2011-07-28 ＰＲＩＳＭ ＢｉｏＬａｂ株式会社 アルファへリックスミメティック及び関連の方法
JP2017535573A (ja) 2014-11-25 2017-11-30 バイエル ファーマ アクチエンゲゼルシャフト 置換されたピリドベンゾジアゼピノン誘導体およびそれの使用
JP7195027B2 (ja) 2018-12-27 2022-12-23 ホロスメディック 新規の化合物およびこれを含む抗癌活性増進用薬学組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517187A (en) * 1982-10-18 1985-05-14 Pennwalt Corporation 1,3,4,6,7-11b-Hexahydro-7-phenyl-2H-pyrazino[2,1-a]isoquinolines methods of preparation, and use as antidepressants
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
PE20010955A1 (es) 1999-12-21 2001-10-11 Procter & Gamble Compuestos mimeticos de peptidos de giros beta y procesos para su fabricacion
JP4101054B2 (ja) * 2000-11-08 2008-06-11 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
KR20060127413A (ko) 2003-11-25 2006-12-12 카이론 코포레이션 항암제로서의 퀴나졸리논 화합물
US9604998B2 (en) * 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
KR101878650B1 (ko) * 2016-10-26 2018-07-16 연세대학교 산학협력단 내성암의 내성 극복 또는 치료용 약학 조성물
WO2018130124A1 (fr) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 Composé tricyclique utilisé en tant que régulateur sélectif du récepteur des œstrogènes et son utilisation
CN108314680A (zh) * 2017-01-16 2018-07-24 凯惠科技发展(上海)有限公司 一种含芳环化合物、其制备方法、药物组合物及应用
CN109748873B (zh) * 2017-11-08 2021-02-02 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
WO2020139044A1 (fr) * 2018-12-27 2020-07-02 홀로스메딕 주식회사 Nouveau composé et composition pharmaceutique le comprenant pour renforcer l'activité anticancéreuse
KR20220000853A (ko) * 2020-06-26 2022-01-04 홀로스메딕 주식회사 신규한 화합물의 제조방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030907A1 (fr) 2001-10-09 2003-04-17 Myriad Genetics, Inc. Mimetiques de coudes inverses et composition et procedes afferents
WO2004035581A1 (fr) 2002-10-18 2004-04-29 Ono Pharmaceutical Co., Ltd. Composes de derives spiroheterocycliques et medicaments contenant lesdits composes comme principe actif
JP2011500774A (ja) 2007-10-26 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体
JP2011522037A (ja) 2008-06-06 2011-07-28 ＰＲＩＳＭ ＢｉｏＬａｂ株式会社 アルファへリックスミメティック及び関連の方法
JP2017535573A (ja) 2014-11-25 2017-11-30 バイエル ファーマ アクチエンゲゼルシャフト 置換されたピリドベンゾジアゼピノン誘導体およびそれの使用
JP7195027B2 (ja) 2018-12-27 2022-12-23 ホロスメディック 新規の化合物およびこれを含む抗癌活性増進用薬学組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Mauro Niso et al.，ChemMedChem，2013年，8(12)，2026-2035，DOI: 10.1002/cmdc.201300291
REGISTRY（STN）[online]，Entered STN：2011.03.21 [検索日 2023.03.17]CAS登録番号 1268963-36-5
REGISTRY（STN）[online]，Entered STN：2011.03.21 [検索日 2023.03.17]CAS登録番号 1268964-53-9
REGISTRY（STN）[online]，Entered STN：2014.09.12 [検索日 2023.03.17]CAS登録番号 1622487-62-0

Also Published As

Publication number Publication date
CN114630830A (zh) 2022-06-14
AU2020374208A1 (en) 2022-05-26
EP4053127A4 (fr) 2023-11-29
JP2023500857A (ja) 2023-01-11
KR20210052322A (ko) 2021-05-10
BR112022007998A2 (pt) 2022-07-05
IL292631A (en) 2022-07-01
US20230019094A1 (en) 2023-01-19
EP4053127A1 (fr) 2022-09-07
AU2020374208B2 (en) 2024-03-14
CA3159791A1 (fr) 2021-05-06
KR102622152B1 (ko) 2024-01-08
MX2022004739A (es) 2022-07-19
WO2021086038A1 (fr) 2021-05-06

Similar Documents

Publication Publication Date Title
CN108026026B (zh) 作为化疗剂的β-取代的β-氨基酸和类似物及其应用
TWI389895B (zh) 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
AU2017382405A1 (en) Compositions and methods for inhibiting arginase activity
CA3093851A1 (fr) Composes 1,1'-biphenyle substitues, analogues de ceux-ci, et procedes les utilisant
WO2016131414A1 (fr) Dérivé d'acide chénodésoxycholique deutéré et composition pharmaceutique comprenant un composé à base de celui-ci
TWI403320B (zh) 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
JP7195027B2 (ja) 新規の化合物およびこれを含む抗癌活性増進用薬学組成物
BRPI0618522A2 (pt) diaril uréia para o tratamento de hipertensão pulmonar
JP2018509441A (ja) 水溶性プロドラッグ
JP2019501977A (ja) キナゾリン誘導体、そのための調製方法、医薬組成物、および適用
CN115916750A (zh) 用于制备具有经取代的苯基或吡啶基部分的serd三环化合物的方法
JP7471685B2 (ja) 新規な化合物およびそれを含むがんの予防または治療用薬学組成物
US20190321345A1 (en) GLUT4 Selective Inhibitors for Cancer Therapy
WO2018200571A1 (fr) Analogues de 2,3-dihydro-1h-indène substitués et leurs méthodes d'utilisation
US9402850B2 (en) BAX agonist, compositions, and methods related thereto
JP2019521193A (ja) 抗癌剤としての４−アニリノ−キノリン化合物
JP7229482B2 (ja) 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤
US20240101562A1 (en) Novel compound, and pharmaceutical composition for preventing or treating resistant cancer, comprising same
TW201930268A (zh) 吲哚胺2,3-雙加氧酶抑制劑以及它們在醫學上的應用
RU2801811C1 (ru) Новое соединение и содержащая это соединение фармацевтическая композиция для предотвращения или лечения рака
CN110049768B (zh) 酚噻嗪衍生物及其使用方法
KR102640385B1 (ko) 고혈압 및/또는 폐 섬유증 치료용 조성물
RU2781282C1 (ru) Новое соединение и содержащая его фармацевтическая композиция для повышения противораковой активности
TW202330015A (zh) 作為治療劑之肽微管蛋白抑制劑之肽結合物
WO2024018403A1 (fr) Composés d'imidazoamide substitués et leurs procédés d'utilisation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240403

R150 Certificate of patent or registration of utility model

Ref document number: 7471685

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150